Assay Development Formulation
Resume:
Gwangseong Kim
734-***-**** / ********@*****.*** / Lexington, MA, 02421
https://www.linkedin.com/in/gwangseong-kim-45768140, US Permanent Resident
Summary
IVD assay development and bioconjugation
oInnovated antibody-based rapid pathogen diagnostics technologies (8hr turnaround time, launched a startup company, Kytaro)
oCommercialized antibody conjugated floating microbeads for cell isolation (launched a startup company, Akadeum)
oCancer targeting using Anti-Her2 conjugated LNPs (post-insertion method into pre-formed LNPs) (SOP)
oPhotosensitizer conjugated biomarker for circulating tumor cell targeted PDT (patent, publication)
oBrain tumor biomarker targeted polymer hydrogel nanoparticle delivery technology (publications)
oInvented heart biomarker targeted photodynamic ablation technology (publications, patents)
Formulation Development
oInvented liposomal formula for clinical stage COVID-19 therapy (Contributed to CMC, 1 IND submission, Phase III ongoing, patents, publications)
oDeveloped liposomal formula for immuno-cancer therapy (Contributed to CMC, 2 IND submission)
oContributed to GMP material sourcing, purity testing, stability testing, issuing COA, etc. Following QbD principle
oLed high-throughput oral formulation screening using ~500 GRAS excipients (patent)
oDeveloped reverse-thermogelling nasal formulation using cellulosic polymers and excipients (publication)
oSynthetic lipoprotein (HDL) formulation (publication) and antibody drug conjugate development (publication)
oNano-polymeric hydrogel formulation for cancer therapy, arrhythmia therapy, brain targeting (publications)
oDeep knowledges in extrahepatic targeting strategies, endosomal escape, SORT LNPs, Ionizable lipids, etc.
Bioanalytical/Analytical Development
oLC-MS method validation for liposomal cancer formulation (pre-clinical GMP tox, PK, 2 IND submission)
oLC-MS method development for drug metabolism studies and biodistribution studies
oExtremely urgent method validation for liposomal COVID-19 therapy (1 IND submission, phase III)
oSPE incorporated LC-MS method development/validation for released/encapsulated PK analysis
oHPLC/LC-MS method development for high-throughput formulation screening (small/macromolecules)
oDeveloped HPLC method for isomer separation in various biomatrices (patent)
oSustained release quantification using USP dissolution (proteins/fatty acids) and dialysis (small molecules)
oDeveloped SEC-HPLC based stability testing protocols and shelf-life determination
oTransferred methods to CROs for Tox studies and clinics for COVID and CMOs for manufacturing
Drug Discovery
oIndirect contribution to computational anti-folate cancer drug derivatives selection and GMP manufacturing
oComputational poly-glutamated isomer structure prediction and contribution to GMP manufacturing
oResulted in 4 pipeline products and 2 IND submissions (ASCO presentation)
oUnderstanding/knowledge in AI driven LNP development (AGILE)
Professional Experiences
Principal Scientist / Cambridge Site Head, VitaKey, 03/2022 - 03/2025
oDirected multiple R&D programs on small molecules/macromolecules Oral dosage platforms for commercial and government projects utilizing DOE and QbD principles
oDesigned/established precision delivery technologies, enhancing bioavailability and stability for oral delivery applications for food/nutraceuticals.
oFiled patents for innovative liquid formulation method using microemulsion and LNP/liposomal/SLNP sustained release system through digestion process in GI tract.
oLed high-throughput formulation screening with over 500 GRAS excipients for lipid formulations / permeation
oContribute to CMC for scale up and performed product validation
oLed high-throughput stability testing (temperature, oxidation, light, impurity, chemical id, storage conditions, accelerated stability) and developed various finish/filling/packaging according to stability
oSkills: HPLC, LC-MS, TFF, UF-DF, NFF, microfiltration, nanofiltration, ultrafiltration, dialysis, method transfer to CROs and Toll manufacturers
Principal Scientist, LEAF Pharmaceuticals / LEAF4Life, 08/2017 – 02/2022
oContributed to develop oncology and COVID-19 therapy programs from pre-IND to clinical phases (CMC and Bioanalytical)
oParticipated in liposomal formulation development of antifolate drugs for NSCLC, CRC, TNBC, etc. with in vivo tumor model development for them, resulting in 2 IND submissions (CMC and Bioanalytical)
oInvented a liposomal formulation and developed it as a COVID-19 therapy pipeline (leading formulation, scale-up in pre-clinical stage, bioanalytical development and PK analysis in clinical stage), resulting in an IND submission, a Clinical Phase III, leading to Emergency Use Authorization in France
oPartnered with multiple CROs and CMOs to achieve critical project milestones efficiently, clinic readiness (API manufacturing, cGMP, mass-scale production of formulations), ensuring regulatory compliance.
oSkills: HPLC, LC-MS, TFF, UF-DF, NFF, microfiltration, nanofiltration, LNP formulation, PK analysis, ICH validation (linearity, accuracy/precision, LOD, LOQ, CV, etc.), method transfers to CROs and CMOs
Chief Technology Officer, Kytaro Inc, 05/2014 – 06/2017
oDeveloped a proprietary medical diagnosis technology by antibody conjugation for pathogen immuno-enrichment and high value cell isolation
oImmuno-electro biosensor research and developed a technology for rapid diagnostics for blood/food.
oDeveloped phototherapy using antibody-drug conjugates for circulating tumor cell selective cell killing
oManaged investor communications, and SBIR/STTR funding applications.
oSkills: HPLC, microfiltration, nanofiltration, dialysis, PCR, flow cytometry, microbiology, immunosensors
Founding Chief Technology Officer, Akadeum Life Sciences, 08/2013 – 04/2014
oLaunched a startup for proprietary 2-beads cell isolation/purification method
oRare cell isolation/detection/purification
oAwarded National Science Foundation Innovation Corps (NSF I-CORPS) fund, 2014
oBusiness development and customer discovery
oSkills: Mammalian cell cultures, bacterial cultures, conjugation, flow cytometry, lateral flow assays
Team leader, DOW Chemical – University of Michigan, 01/2012 – 07/2013
oLed the development of intra nasal formulation using DOW cellulosic polymers
oDiscovered an induced thermo-gelation at body temperature by polymeric excipients
oBuilt up expertise in nasal physiology and formulation parameters for nasal drug delivery (excipients, epithelial permeability, bioavailability, etc.)
oIn depth experience in HPLC, drug permeation through biological membranes, various microscopy, particle tracking, spray particle formation, adhesive force measurement etc.
oDeveloped synthetic high-density lipoprotein (HDL) nanoparticles and their drug delivery applications
oSkills: Rheometer, in vivo/ex vivo imaging, Franz cell, TEER, DSC, ITC, SEM, HPLC, etc.
Postdoctoral Research fellow, University of Michigan, Ann Arbor, 05/2008 – 12/2011
oInvented targeted drug delivery to brain cancers, breast cancers, and heart
oDeveloped conjugation chemistry for peptide, protein, antibody, nucleotides, sugars
oCell cultures and various cell-based bioassays for cell viability, proliferation, intracellular trafficking, etc.
oNanoparticle-cell interaction: ligand-receptor binding, cell entry, intracellular trafficking
oTherapies, diagnostics, biosensing, biomedical imaging
oSkills: Confocal, Laser, conjugation, sol-gel, emulsion-polymerization, DLS, SLS, TFF, flow cytometry, biosensors, etc.
Education
oPhD at University of Michigan, Ann Arbor, Biomedical Engineering, 2008
oMS at University of Michigan, Ann Arbor, Biomedical Engineering
oBS at Hanyang University, Seoul, Korea, Chemical Engineering
Proficient Skills
oKnowledge/experiences in HPLC, GC, and LC-MS (Triple quad and Orbitrap high-resolution MS), ligand binding assays, particle characterization, water activity, spectroscopy, rheology, calorimetry (DSC), protein quantification, Gene quantification, PCR, flow cytometry, MACS, Confocal imaging, SEM/TEM
oVarious downstream processing related techniques: LLE, SPE, dialysis, TFF, NFF, centrifugation, desalting, dissolution (USP), stability testing, endotoxin clearance, gas-heading, fill/finish, Leachable/extractable
oFormulation development: (liquid, solid, gel, sprayable, injectable, oral, parenteral) for max efficacy/safety
oProficiency in analysis tools: Analyst, WinNonlin (PK), Prism
oAdministrative tools: Asana, Monday.com, LabGuru (LIMS)
Publications / Patents / Training
o46 publications including Journal of Controlled Release, Arteriosclerosis, Thrombosis, and Vascular Biology, Small, Analytical Chemistry, Scientific Reports (NPG), Nanoscale, Heart Rhythm, Journal of Materials Chemistry, etc. (https://scholar.google.com/citations?hl=en&user=BQHKE4UAAAAJ&view_op=list_works&sortby=pubdate)
o10 patents and provisional filing (https://patents.justia.com/search?q=gwangseong+kim)
oProject management training, MassBioEd (2020)
End of Resume (Optional details in following pages as a full CV)
<Peer-reviewed publications>
1.P Mertes, O Collange, P Coliat, M Banerjee, M Diringer, A Roche, X Delabranche, V Chaban, M Voegelin, A Bernard, V Sartori, N Laurent, M Velten, N Dhindsa, J Defuria, G Kim, Z Xu, M Theodorou, Z Huang, K Khalifa, B Geng, C Niyikiza, V Moyo, P Gizzi, P Villa, A Detappe, X Pivot, “Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation” Journal of Controlled Release 336 (2021): 252-261.
2.G Kim, A Nyinawabera, Z Xu, J DeFuria, A Sezibera, Y Cui, B Geng, Intratumoral exposure levels of pentaglutamated pemetrexed following treatment with LEAF-1401 and pemetrexed. Journal of Clinical Oncology 38 (15_suppl), 3524-3524
3.Kim G, Karbaschi M, Cooke M, Gaitas A. Light-based methods for whole blood bacterial inactivation enabled by a recirculating flow system. PhotochemPhotobiol. 2018;94(4):744-751. doi:10.1111/php.12899
4.G. Kim, H. Vinerean, A. Gaitas, “A Novel Pathogen Capturing Device for Removal and Detection.” Scientific Reports, 7, Article number: 5552 (2017)
5.G. Kim, A. Gaitas, "Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells." PLoS ONE, 2015, 10(5): e0127219. doi:10.1371/journal.pone.0127219
6.K. Hansen, G. Kim, K. G. H. Desai (equally contributing first authors), H. Patel, K. F. Olsen, J. Curtis-Fisk, & S. P. Schwendeman, "Feasibility investigation of cellulose polymers for mucoadhesive nasal drug delivery applications." Molecular Pharmaceutics, (2015), 12(8), 2732-2741.
7.A. Gaitas, G. Kim, "Chemically Modified Plastic Tube for High Volume Removal and Collection of Circulating Tumor Cells", PLoS ONE, 2015, 10(7): e0133194. doi:10.1371/journal.pone.0133194
8.A. Gaitas, G. Kim, "Inductive heating kills cells that contribute to plaque: a proof-of-concept." PeerJ, (2015), 3, e929.
9.H. K. Yoon, A. Ray, Y. Koo Lee, G. Kim, X. Wang, R. Kopelman, "Polymer–protein hydrogel nanomatrix for stabilization of indocyanine green towards targeted fluorescence and photoacoustic bio-imaging." Journal of Materials Chemistry B, 2014, 1(41): 5611-5619.
10.X. Lou, G. Kim, H. K. Yoon, Y. Koo Lee, R. Kopelman and E. Yoon, "A high-throughput photodynamic therapy screening platform with on-chip control of multiple microenvironmental factors", Lab on a Chip, 2014,14, 892-901
11.U. Avula, H. Yoon, G. Kim, R. Kopelman, and J. Kalifa, "Left atrium nanoplatform-enabled targeted photodynamic ablation: preliminary results in vivo." Heart Rhythm, 2013, 10(11), 1747.
12.DO Sviridov, AA Schwendeman, G Kim, J Stonik, S Turner, AT Remaley, The Association of 5A Peptide With Sphingomyelin Increases Its Ability to Efflux Cholesterol Both in vitro and in vivo, Arteriosclerosis, Thrombosis, and Vascular Biology 33 (suppl_1), A448-A448
13.H. K. Yoon, A. Ray, Y. Koo Lee, G. Kim, X. Wang, and R. Kopelman, "Polymer-Protein Hydrogel Nanomatrix for Stabilization of Indocyanine Green towards Targeted Fluorescence and Photoacoustic Bio-imaging.", Journal of materials chemistry. B, Materials for biology and medicine. 11/2013; 1(41).
14.L. Karamchand, G. Kim (equally contributing first authors), S Wang, H. Hah, A. Ray, R.Jiddou, Y. Koo Lee, M. A. Philbert, and R. Kopelman “Modulation of hydrogel nanoparticle intracellular trafficking by multivalent surface engineering with tumor targeting peptide”,Nanoscale, 2013,5, 103**-*****
15.U. M. R. Avula, G. Kim (equally contributing first authors), Y. Koo Lee, F.Morady, R. Kopelman, and J. Kalifa, “Cell-Specific Nanoplatform-Enabled Photodynamic Therapy for Cardiac Cells”, Heart Rhythm, 2012, 9(9), 1504-1509
16.G. Nie, H. J. Hah, G. Kim (equally contributing first authors), Y. Koo Lee, M. Qin, T. S. Ratani, P. Fotiadis, A. Miller, A. Kochi, D. Gao, T. Chen, D. A. Orringer, O. Sagher, M. A. Philbert, and R. Kopelman, “Targeted Hydrogel Nanoparticles with Covalently Linked Coomassie Blue for Brain Tumor Delineation Visible to the Surgeon’s Eyes”, Small, 2012, 8(6), 884-891
17.S. Wang, G. Kim, Y. Koo Lee, H. J. Hah, M. Ethirajan, R. K. Pandey, and R. Kopelman, “Multifunctional Biodegradable Polyacrylamide Nanocarriers for Cancer Theranostics—A “See and Treat” Strategy”, ACS Nano, 2012, 6(8), 6843-6851
18.B. Koh, G. Kim, H. K. Yoon, J. B. Park, R. Kopelman, and W. Cheng, “Fluorophore and Dye-Assisted Dispersion of Carbon Nanotubes in Aqueous Solution”, Langmuir, 2012, 28(32), 11676–11686
19.A. Ray, Y. Koo Lee, G. Kim and R. Kopelman, “Two-photon fluorescence imaging super-enhanced by multi-shell nanophotonic particles, with application to subcellular pH”, Small, 2012, 8(14), 2213-2221
20.G. Nie, D.Si,G.Kim,Z. Shi, T. S. Ratani,Y. Koo Lee, C. A. Fierke, and R.Kopelman,“A Novel Nonionic, Multi-Surfactant System and Separation Method for the Synthesis of Active Carbonic Anhydrase Nanoparticles”, Advanced Materials Research, 2012, v399-401, 509-513
21.A. Ray, X. Wang, Y. E. Koo Lee, H. Hah, G. Kim, T. Chen, D. Orringger, O. Sager and R. Kopelman, "Targeted blue nanoparticles as photoacoustic contrast agent for brain tumor delineation", Nano Research, 2011, 4(11), 1163-1173
22.R. Kopelman, Y.E.K. Lee, S. Wang, H.J. Hah, G. Kim, M. Nie, M. Qin, O. Sagher, D. Orringer, M. Philbert, K. Herrmann, R. Pandey"Why use nanoparticles as photosensitizers for PDT?." Photodiagnosis and Photodynamic Therapy 8.2 (2011): 157-158.
23.S. Wang, W. Fan, G. Kim, H. J. Hah, Y. Koo Lee, R. Kopelman (University of Michigan), M. Ethirajan, A. Gupta, L. N. Goswami, P.Pera, J. Morgan, R. K. Pandey (Roswell Park Cancer Institute), “Novel Methods to Incorporate Photosensitizers into Nanocarriers for Cancer Treatment by Photodynamic Therapy”, Lasers in Surgery & Medicine, 2011, 43, 686–695
24.A. Ray, Y.E Koo Lee, T. Epstein, G. Kim and R. Kopelman, "Two photon nano PEBBLE sensor: subcellular pH mapping", Analyst, 2011, 136(18), 3616-3622
25.M. Qin, H. J. Hah, G. Kim, G. Nie, Y. Koo Lee and R. Kopelman, “Methylene blue covalently loaded polyacrylamide nanoparticles for enhanced tumor-targeted photodynamic therapy”, Photochemical & Photobiological Sciences, 2011, 10, 832-841
26.G. Kim, H. Xu, Y. L. Koo, M. Philbert, and R. Kopelman, “Nanoencapsulation Method for High Selectivity Sensing of Hydrogen Peroxide inside Live Cells”, Analytical Chemistry, 2010, 82(6), 2165–2169, This article was highy the journal, Feb/2010
27.H. J. Hah, G. Kim, Y. K.Lee,D. A. Orringer, O.Sagher, M. A. Philbert, and R. Kopelman, “MethyleneBlue-Conjugated Hydrogel Nanoparticles and Tumor-Cell Targeted Photodynamic Therapy”, MacromolBiosci. 2011, Jan 10, 11(1), 90-99
28.Y. K. Lee, E. Ulbrich,G. Kim, H. J. Hah, C. Strollo, W. Fan, R. Gurjar, S. M. Koo, and R. Kopelman, “NIR fluorescent nanosensors for tumor hypoxia with nanoparticle matrix tailored sensitivity”, Analytical Chemistry, 2010, 82(20), 8446-8455
29.D. A. Orringer, Y. E. Koo, T. Chen, G. Kim, H. J. Hah, H. Xu, S. Wang, R. Keep, M. Philbert, R. Kopelman, O. Sagher “In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation.” Neurosurgery, (2009), 64(5), 965-971
30.A. Johnson-Buck, G. Kim, S. Wang, H. J. Hah, and R. Kopelman “Fabrication, Characterization, and Spectral Properties of Indigo Blue Nanocrystals”, Molecular Crystals and Liquid Crystals, (2008), 501, 138-144
31.T. D. Horvath, G. Kim, R. Kopelman, S. Ashkenazi, “Ratiometric photoacoustic sensing of pH a “Sonophore””, Analyst, (2008), 133, 747-749.
32.G. Kim, S. Huang, K. C. Day, M. O’Donnell, R.R. Agayan, M. A. Day, R. Kopelman and S. Ashkenazi, “Indocyanine Green embedded PEBBLEs as a Contrast Agent for Photoacoustic Imaging”, Journal of Biomedical Optics, (2007), 12(4), 044020 This article was also selected for Sep. 10. 2007 issue of Virtual Journal of Nanoscale Science and Technology
33.R. G. Reddy, M.S. Bhojani, P. McConville, M. Jonathan, B. A. Moffat, D. E. Hall, G. Kim, Y. L. Koo, M. J. Woolliscroft, J. V. Sugai, T. D. Johnson, M. A. Philbert, R. Kopelman, A. Rehemtulla, B. D. Ross, “Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors.”,Clin. Cancer Res., (2006), 12(22), 6677-6686
<Non-peer-reviewed publications / Dissertation / Proceedings / Book chapters / Preprints>
1.G. Kim, A. Gaitas, "An introduction to antibiotic-free techniques to eliminate Staphylococcus aureus from blood" BioRxiv, doi: http://dx.doi.org/10.1101/030072
2. A. Gaitas, R. Malhotra, K. Pienta, G. Kim, “Response to “Comment on ‘A method to measure cellular adhesion utilizing a polymer micro-cantilever’” Appl. Phys. Lett. 104, 236104 (2014)
3. A. Ray, H. K. Yoon, H. Ryu, Y. Koo Lee, G. Kim, X. Wang, and R. Kopelman, "Polyacrylamide based ICG nanocarriers for enhanced fluorescence and photoacoustic imaging", Proc SPIE 02/2013; DOI:10.1117/12.2002921
4. G. Kim, Y. Koo Lee, and R. Kopelman, “Hydrogen Peroxide (H2O2) detection with Nanoprobes for Biological Applications: A Mini-Review”, in Oxidative Stress and Nanotechnology: Methods and Protocols, Methods in Molecular Biology Volume 1028, 2013, 101-114, Humana Press, 2012
5.A.Ray,X.Wang,Y. Koo Lee, H. J. Hah,G. Kim, T. Chen, D. A.Orrienger,O.Sagher, R. Kopelman, “Photo-acoustic imaging of blue nanoparticle targeted brain tumor for intra-operative glioma delineation”, Proc. SPIE, (2011), 8089, 808906.
6.X. Lou, G. Kim, Y. Koo, R. Kopelman, and E. Yoon, “Investigating Photodynamic Efficiency of Tumor Targeted Nanoparticular Photosensitizer Using Microfludic Chips”, Proceedings - MicroTAS, 2011, in press
7.X. Low, G. Kim, Y. K. Lee, R. Kopelman, and E. Yoon, “High-Throughput Screening of Photodynamic Therapy (PDT) from Multiple Parameter Assays of 1,000 Different Conditions in a Single Chip”, Proceedings - MicroTAS, Oct/2010, in press
8.G. Kim, “Development of nanoparticle based tools for reactive oxygen species and related biomedical applications.” Doctoral dissertation, (2008), 149 pp.The commercial publication of this dissertation was offered by VDM Publishing House Ltd.(Beau Bassin, Mauritius)
9.B. Ross, A. Rehemtulla, Y. L. Koo, R. Reddy, G. Kim, C. Behrend, S. Buck, R. J. Schneider, M. A. Philbert, R. Weissleder, R. Kopelman, “Photonic and magnetic nanoexplorers for biomedical use: from subcellular imaging to cancer diagnostics and therapy”, Proc. SPIE, (2004), 5331, 76-83
<Patents>
1.Nutraceutical particles (Publication number: WO2024006539A1)
2.CAROTENOID COMPOSITIONS AND USES THEREOF (Publication number: 202********)
3.Systems and methods for targeted imaging and ablation of cardiac cells (Patent number: 11369683)
4.CAROTENOID COMPOSITIONS AND USES THEREOF (Publication number: 202********)
5.Systems and methods for targeted imaging and ablation of cardiac cells (Patent number: 10512691)
6.PRE-CONCERTATION APPARATUS & METHOD (Publication number: 201********)
7.BLOOD CLEANSING AND APPARATUS & METHOD (Publication number: 201********)
8.BLOOD CLEANSING SYSTEM (Publication number: 201********)
9.Photoacoustic indicators (Patent number: 7576334)
<Presentation at international/national conferences>
1.ASCO Annual Meeting 2020, “Intratumoral exposure levels of pentaglutamated pemetrexed following treatment with LEAF-1401 and pemetrexed.”
2.emergeUSA 2016 (Miami, FL)
3.PITTCON 2011 (Atlanta, GA), “Investigating cancer targeting and endocytotic internalization for targeted drug delivery with nanocarriers”
4.AAPS 2009 (Los Angeles, CA), “Multifunctional nanoplatform for cancer targeting, optical imaging and photodynamic therapy”
5.Fifth Annual Biomedical Research Symposium on “Image-Guided Therapy” 2008 (Ann Arbor, MI) poster session, “Multi-Functional Nanoplatforms for Cancer Diagnostics and Photodynamic Therapy”
6.PITTCON 2007 (Chicago, IL) poster session, “Development of Indocyanine Green embedded nanoparticles as a contrasting agent for photoacoustic imaging and photodynamic therapy”
7.PITTCON 2006 (Orlando, FL) poster session, “Development of novel nanoparticle type fluorescent probes for specific reactive oxygen species (ROSs) detection”
8.PECRUM 2005 (Ann Arbor, MI) poster session, "Evaluation of singlet oxygen (1O2) generation by photodynamic therapy (PDT) system using 1,3-diphenylisobenzofuran (DPIBF) doped Ormosil (Organically Modified Silicate) PEBBLE (Probe Encapsulated By Biologically Localized Embedding)
9.PITTCON 2005 (Orlando, FL) oral presentation, “Sensitivity of 1,3-diphenylisobenzofuran (DPIBF) embedded in organically modified silicate (Ormosil) nanoprobes towards singlet oxygen in aqueous media”
10.PITTCON 2004 (Chicago, IL) poster session, “Evaluation of singlet oxygen production with 1,3-di-phenylisobenzofuran (DPIBF) free dye and DPIBF embedded nanoparticles”
<Press Release>
1.Fine tuning cardiac ablation could lead to quicker results for patients with arrhythmias (http://www.uofmhealth.org/news/finetuningablation-0724)
<Participated grants>
1.NCI ContractNO-1-CO-37123 (R. Kopelman)
2.Keck foundation Grant N004497 (M.A. Philbert and R. Kopelman)
3.NIH Grant 1R41 CA 130518-01A1 (R. Kopelman)
4.NIH Grant NIBIB R01 EB007977 and NIBIBR000262 (R. Kopelman)
5.NIH/NCI R33CA125297 (R. Kopelman) and NCI/NIH Nanoplatform Grant (CA 119358)
6.MICHR Pilot Grant Program (J. Kalifa)
7.R21 NIH project titled “Myocyte-specific nanoplatform-enabling photodynamic cardiac ablation”
8.NSF Innovation CORPS Jan. 2014 (Funded, G. Kim)
9.NSF SBIR (Proposal 1416083 submitted, B. McNaughton and G. Kim)
10.NSF SBIR (Proposal 1647911 submitted, G. Kim)
11.NIH 1 R21 AI133198-01 (A. Gaitas, G. Kim)
12.NSF SBIR (Proposal 1722106 submitted, G. Kim
Contact this candidate